UCERIS, developed by Salix Pharmaceuticals, is a rectally administered corticosteroid. The tentative FDA approval means the product meets quality, safety and efficacy standards, but awaits resolution of patient issues before receiving final approval.
More articles on gastroenterology:
19 things to know about GI compensation & satisfaction in 2014
How has the Obama presidency affected the field of GI?
Will CMS cover virtual colonoscopy?
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
